Hotel des Indes (The Hague)

Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline

Retrieved on: 
Tuesday, November 7, 2023
MDAX, Frankfurt Stock Exchange, IND, Therapy, ISIN, EVO, Risk, Partnership, Hotel des Indes (The Hague), Dew point, IndiGo, AI, Sales, Pharmaceutical industry, Evotec

Under the collaboration, Evotec will facilitate the rapid development of Dewpoint’s oncology assets using Evotec’s fully integrated clinical-enabling INDiGO platform to de-risk and accelerate the path to clinical testing.

Key Points: 
  • Under the collaboration, Evotec will facilitate the rapid development of Dewpoint’s oncology assets using Evotec’s fully integrated clinical-enabling INDiGO platform to de-risk and accelerate the path to clinical testing.
  • Dr. Matthias Evers, Chief Business Officer of Evotec, commented, “We are excited to enter this strategic development partnership with Dewpoint.
  • By combining our complementary expertise, Evotec’s development platform will serve as the capital-efficient IND engine for this highly collaborative partnership.
  • We look forward to working closely together with their team to make Dewpoint’s groundbreaking innovations available to patients.”
    “Dewpoint’s strategic partnership with Evotec leverages the world-class speed of their development platform to accelerate our oncology assets into the clinic.

EQS-News: Evotec and Dewpoint Therapeutics enter strategic partnership in oncology

Retrieved on: 
Tuesday, November 7, 2023
MDAX, IND, Therapy, ISIN, Frankfurt Stock Exchange, INDIGO, EVO, Risk, Partnership, A.I, Hotel des Indes (The Hague), Dew point, IndiGo, Sales, Pharmaceutical industry, Evotec

The partnership brings together Dewpoint’s advanced oncology pipeline programmes discovered using its groundbreaking condensate biology and A.I.

Key Points: 
  • The partnership brings together Dewpoint’s advanced oncology pipeline programmes discovered using its groundbreaking condensate biology and A.I.
  • Dr Matthias Evers, Chief Business Officer of Evotec, commented: “We are excited to enter this strategic development partnership with Dewpoint.
  • By combining our complementary expertise, Evotec’s development platform will serve as the capital-efficient IND engine for this highly collaborative partnership.
  • We look forward to working closely together with their team to make Dewpoint’s groundbreaking innovations available to patients.”
    “Dewpoint’s strategic partnership with Evotec leverages the world-class speed of their development platform to accelerate our oncology assets into the clinic.

Bionomics appoints Spyridon “Spyros” Papapetropoulos as President and Chief Executive Officer

Retrieved on: 
Thursday, December 15, 2022
Biogen, Corporations Act 2001, Psychiatry, Social anxiety disorder, Employment, Michele Cavion, CNS, ASX, Extraordinary general meeting, School, Public sector, Faculty, EVP, Central nervous system disease, Central nervous system, Vigil, Doctor of Philosophy, Neurology, BNO, Pfizer, SVP, EGM, MD, Neurodegeneration, Corporation, BNC210, Non-executive director, Hotel des Indes (The Hague), Allergan, Appendix (anatomy), Post-traumatic stress disorder, Therapy, FOR, University, Development, Patient, Pharmaceutical industry, Security (finance), Bionomics, Appendix

as President and Chief Executive Officer (CEO), effective 5 January 2023.

Key Points: 
  • as President and Chief Executive Officer (CEO), effective 5 January 2023.
  • Spyros is an experienced biopharmaceutical executive, a recognized neuroscientist/neurologist, and change agent with a 25-year career focused on CNS disorders.
  • Prior to joining Vigil, he served as Chief Development Officer, and SVP, Head of Development at Acadia Pharmaceuticals Inc., CEO at SwanBio Therapeutics, and EVP of Research & Development and Chief Medical Officer at Cavion.
  • The additional options are part of the compensation of Dr. De Souza for his period as Executive Chair of Bionomics.

Cartier has opened a new boutique at the P.C. Hooftstraat in Amsterdam

Retrieved on: 
Thursday, December 1, 2022
The Hague, Maison, Certification, Creativity, LEED, Lacquer, Piet Mondrian, P.C. Hooftstraat, Human, Biophysical environment, Exposition, De Stijl, Hotel des Indes (The Hague), Jewellery, Koningsplein, Johannes Vermeer, Cartier

AMSTERDAM, Dec. 1, 2022 /PRNewswire/ -- This winter, a new chapter begins for Cartier in Amsterdam with the opening of the new boutique at the P.C. Hooftstraat 129. Studio Parisien carried the boutique's design from the facade to the interiors, inspired and supported by Dutch local talents.

Key Points: 
  • "I am delighted to announce the opening of the new Cartier boutique in Amsterdam.
  • The new boutique will be an open window to timeless design, celebrating creativity and craftsmanship.
  • AMSTERDAM, Dec. 1, 2022 /PRNewswire/ -- This winter, a new chapter begins for Cartier in Amsterdam with the opening of the new boutique at the P.C.
  • The new Amsterdam boutique meets the highest ecological standards as directed by the globally recognized Leadership in Energy and Environmental Design (LEED) certification.

Cartier has opened a new boutique at the P.C. Hooftstraat in Amsterdam

Retrieved on: 
Thursday, December 1, 2022
The Hague, Maison, Certification, Creativity, LEED, Lacquer, Piet Mondrian, P.C. Hooftstraat, Human, Biophysical environment, Exposition, De Stijl, Hotel des Indes (The Hague), Jewellery, Koningsplein, Johannes Vermeer, Cartier

AMSTERDAM, Dec. 1, 2022 /PRNewswire/ -- This winter, a new chapter begins for Cartier in Amsterdam with the opening of the new boutique at the P.C. Hooftstraat 129. Studio Parisien carried the boutique's design from the facade to the interiors, inspired and supported by Dutch local talents.

Key Points: 
  • "I am delighted to announce the opening of the new Cartier boutique in Amsterdam.
  • The new boutique will be an open window to timeless design, celebrating creativity and craftsmanship.
  • AMSTERDAM, Dec. 1, 2022 /PRNewswire/ -- This winter, a new chapter begins for Cartier in Amsterdam with the opening of the new boutique at the P.C.
  • The new Amsterdam boutique meets the highest ecological standards as directed by the globally recognized Leadership in Energy and Environmental Design (LEED) certification.

Keiretsu Forum Held First South-East Gathering to Showcase 12 Innovative Growth-Stage Companies Actively Seeking Funding

Retrieved on: 
Wednesday, November 23, 2022
P21-activated kinases, Infection, HRV, Angel Capital Association, Communication, Science, Adolescence, Hotel des Indes (The Hague), Cell, Neuropathic pain, Student, Keiretsu Forum, Patient, Telehealth, PAK1, Faculty, G protein-coupled receptor, Humanetics, Expo, Health, Research, Therapy, Metastasis, See, Water, Mercer University, Biotechnology, Drug discovery, FDA, Financial services, Security (finance), Fine chemical, Medical imaging, Pharmaceutical industry, Pharma

This multi-session showcase gave an in-person and virtual stage to 12 US-based growth stage companies seeking funding (see list below).

Key Points: 
  • This multi-session showcase gave an in-person and virtual stage to 12 US-based growth stage companies seeking funding (see list below).
  • Finding new relationships in a challenging fundraising market is difficult, says Howard Lubert, Area President of Keiretsu Forum.
  • ( See introduction video )
    Keiretsu Forum is a global investment community of accredited private equity angel investors, venture capitalists and corporate/institutional investors.
  • Keiretsu Forum today is a worldwide network of capital, resources, and deal flow with 50+ chapters on four continents.

Keiretsu Forum South-East Announces Impressive Line-Up For First-Ever Investor Capital Expo In Atlanta

Retrieved on: 
Monday, November 7, 2022
Telehealth, Virus, Research, Biofilm, GPCR, Therapy, Biotechnology, Fungus, Industry, PAK1, GLOBE, FDA, Cell, Adult, Neuropathic pain, Communication, COVID-19, HRV, Metastasis, Angel Resource Institute, Keiretsu, CEO, Bacteria, Mercer, Humanetics, Gq alpha subunit, Keiretsu Forum, Angel Capital Association, Health, Adolescence, P21-activated kinases, Seed (TV series), Technology, Hotel des Indes (The Hague), G protein-coupled receptor, Patient, Solution, Video game, Medical imaging, Pharmaceutical industry, Fine chemical, Pharma

Keiretsu Forum is the most active angel group across the U.S, as reported by the Angel Resource Institutes most recent 2021 HALO Report .

Key Points: 
  • Keiretsu Forum is the most active angel group across the U.S, as reported by the Angel Resource Institutes most recent 2021 HALO Report .
  • Keiretsu Forum is a global investment community of accredited private equity angel investors, venture capitalists and corporate/institutional investors.
  • Keiretsu Forum today is a worldwide network of capital, resources, and deal flow with 50+ chapters on four continents.
  • Keiretsu Forum members invest in high-quality, diverse investment opportunities.

Neuraptive Therapeutics Announces Key Organizational Updates to Support the Company’s Advancements in Nerve Repair

Retrieved on: 
Monday, October 24, 2022
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Physician, Therapy, Hotel des Indes (The Hague), NDA, Research and development, Patient, Nerve, Pediatrics, Executive, University, CHOP, Wyeth, Neurology, CEO, Faculty, Associate, Fast Track, Pharmaceutical industry, Management, Pfizer, Research

Neuraptive Therapeutics, Inc., a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries, announced key organizational and financial updates.

Key Points: 
  • Neuraptive Therapeutics, Inc., a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries, announced key organizational and financial updates.
  • Evan Tzanis has been appointed to the role of Chief Operating Officer and Executive Vice President of Research and Development.
  • Additionally, Mr. Tzanis has played an integral role guiding the company through significant organizational transition and fundraising.
  • Neuraptive Therapeutics, Inc. is a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries.

CARsgen Releases the First Clinical Batch of CAR T Cells from its RTP GMP Manufacturing Facility in North Carolina

Retrieved on: 
Friday, September 2, 2022
Oncology, Health, Stem Cells, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Cancer, Research Triangle Park, CAR, RTP, CGMP, Board, Hotel des Indes (The Hague), Heme, CMC, Health Canada, Multimedia, PRIME, GMP, Company, FDA, Minister of Health (Canada), Patient, Â, Vaccine, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20220902005075/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220902005075/en/
    CARsgen's RTP GMP Manufacturing Facility (Photo: Business Wire)
    The RTP GMP Manufacturing Facility, with a total gross floor area of approximately 3,300 sq.m, will provide CARsgen additional manufacturing capacity of autologous CAR T-cell products for 700 patients annually to support clinical studies and early commercial launch in North America and Europe.
  • I am very pleased to announce that the RTP Manufacturing Facility has achieved the companys target of releasing the clinical batches for the U.S. patient use in Q3, 2022, said Mr. Richard Daly, President of CARsgen Therapeutics Corporation.
  • The company will accelerate the ongoing clinical studies by providing more promising CAR T-cell products to the global patients.
  • The commencement of clinical production at the RTP GMP Manufacturing Facility will greatly reduce current risks of global supply chain shortage and strengthen the value chain of CARsgen.

Pyxis Oncology Provides Corporate and Financial Update

Retrieved on: 
Tuesday, March 29, 2022
Cancer, University, Catalog, IO, Common stock, Therapy, Private Securities Litigation Reform Act, Investor, Risk, Chicago (franchise), Growth, ADC, GLP, IND, AACR, SEC, Research, Observation, Conference, Webcast, Mab, Immune system, Review, Hotel des Indes (The Hague), Nasdaq, GLOBE, American Academy, Annual report, Escape Room, Patient, Airline, Pharmaceutical industry, Fine chemical, Online gambling, Company

CAMBRIDGE, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today provided a corporate and financial update and reported financial results for the full year ended December 31, 2021.

Key Points: 
  • ET
    CAMBRIDGE, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today provided a corporate and financial update and reported financial results for the full year ended December 31, 2021.
  • License agreement with Biosion adds anti-Siglec-15 to Pyxis Oncologys IO pipeline: Pyxis Oncology announced today it has in-licensed anti-Siglec-15, now referred to as PYX-106, a potentially best-in-class monoclonal antibody which is a novel immune checkpoint.
  • A live webcast can be accessed at https://edge.media-server.com/mmc/p/c8uwd9dr or on the Investors section of the Pyxis Oncology website at ir.pyxisoncology.com .
  • Pyxis Oncology, Inc. is a multi-asset multi-modality company focused on defeating difficult to treat cancers and improving patient lives.